Answers are grounded in this paper and cite their sources.
Background & Aims Elevated FBXO45 expression is associated with human hepatocellular carcinoma (HCC). While TP53 mutations represent a common genetic alteration in HCC, it remains unclear the potential regulatory interplay between TP53 and FBXO45 in modulating HCC progression. Methods We analyzed the relationship between TP53 and FBXO45 in HCC patients. A series of assays were performed to explore the effect of FBXO45 on invasion and metastasis in TP53-mutated HCC cell lines and mouse models. These experimental findings were further validated in clinical samples. Results FBXO45 expression was upregulated in 78.3% (83/106) of HCC patients with TP53 mutation, marking an aggressive subtype. Overexpression of FBXO45 significantly enhanced HCC cell migration and invasion capacity ( p < 0.001), whereas FBXO45 silencing suppressed these effects ( p < 0.01). Mechanistically, FBXO45 promoted TFG Lys103 ubiquitination and then increased its stability. This post-translational modification facilitates the binding of transcription factor ATF2, leading to subsequent upregulation of NF-κB p65 expression and ultimately promoting the migratory and invasive properties of TP53-mutant HCC cells. In vivo validation using an orthotopic xenograft model showed that FBXO45 overexpression significantly promoted HCC lung metastasis incidence (7/9 mice with metastases), while TFG knockdown abrogated this metastatic potential. Clinically, patients exhibiting high co-expression of FBXO45 and TFG defined an aggressive HCC subtype with significantly worse prognosis ( p = 0.0015). Conclusions Our results provide new mechanistic insight into the role of FBXO45 in driving HCC invasion and metastasis. Targeting the TP53-FBXO45-TFG-ATF2-NF-κB axis therefore represents a promising therapeutic approach for treating aggressive HCC with TP53 mutations. Impact and implications This study highlights that FBXO45 is highly expressed in HCC patients with TP53 mutations. FBXO45 promotes HCC lung metastasis by activating the TFG/ATF2/NF-κB/EMT signaling axis. In addition, we found that targeting the TP53/FBXO45/TFG/ATF2/NF-κB axis may be a novel approach for the treatment of metastatic HCC.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: